Targeting CNS Transporters for Treatment of Neurodegenerative Diseases

Author(s): Gabriele Jedlitschky, Markus Grube, Igor Mosyagin, Heyo K. Kroemer, Silke Vogelgesang

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 10 , 2014

Become EABM
Become Reviewer
Call for Editor


Molecular transporters that are expressed in brain, especially at the blood-brain barrier (BBB), are increasingly recognized as possible therapeutic targets in the treatment of neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. Some ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (ABCB1), MRP1 (ABCC1) and BCRP (ABCG2), have been implicated in the clearance of neurotoxic polypeptides that characteristically accumulate in the brain, such as amyloid-β (Aβ) peptides in Alzheimer’s disease. Several lines of evidence also implicate lipid transporters of the A-branch of ABC transporters in pathogenesis. Induction of transporters via the activation of specific nuclear receptors may represent a novel approach to restoring diminished BBB function. On the other hand, transporters in the brain capillary endothelium regulate the permeation of therapeutic compounds into the brain. In addition to the export pumps that limit brain entry of exogenous substances, SLC-type uptake transporters, especially of the OCT (SLC22A) family, are of potential relevance in that they mediate not only the uptake of several drugs used for the treatment of neurodegenerative diseases, but also of certain neurotoxins. Here, we summarize recent findings and novel strategies targeting transporters to reduce brain pathology or to improve drug therapy.

Keywords: ABC transporters, Alzheimer’s disease, beta amyloid, blood-brain barrier, neurodegeneration, organic anion transporters, parkinson’s disease, P-glycoprotein.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1523 - 1533]
Pages: 11
DOI: 10.2174/13816128113199990460
Price: $65

Article Metrics

PDF: 59